Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) General Information
Description
Intellectual property rights for compositions of matter and methods to make and use genome-edited primary B cells. The intellectual property rights include proprietary methods that cover the delivery of a targeted nuclease into the B cell for precise genome engineering and the resultant compositions of matter.
Contact Information
Corporate Office
- Minneapolis, MN
- United States
Corporate Office
- Minneapolis, MN
- United States
Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) FAQs
-
Where is Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) headquartered?
Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) is headquartered in Minneapolis, MN.
-
What industry is Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) in?
Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells)’s primary industry is Buildings and Property.
-
Is Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) a private or public company?
Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) is a Private company.
-
What is Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells)’s current revenue?
The current revenue for Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) is .
-
Who are Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells)’s investors?
Regents of the University of Minnesota has invested in Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells).
-
When was Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) acquired?
Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) was acquired on 27-Mar-2023.
-
Who acquired Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells)?
Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) was acquired by Immusoft.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process